Roivant Sciences (ROIV) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.18

Estimate

-$0.45

Surprise

+58.9%

Revenue (period 2026-09-30)

$35.1M

Score today

4.2/10

Revenue source: xbrl.

Roivant Sciences (ROIV) reported a narrower loss than forecast — adjusted EPS of -$0.18 against the -$0.45 estimate (a 58.9% beat on a still-unprofitable quarter).

• Nvidia To $300? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga, 2026-11-10
• HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $48 — benzinga, 2026-11-10
• Roivant Sciences Q2 2027 Earnings Call Transcript — benzinga, 2026-11-09

TrendMatrix currently rates ROIV Sell at 4.2/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +58.9% surprise compares with a +24.0% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$40.28

Price target

$43.50

Stop

$37.46

Upside to target

+8.0%

Reward-to-risk

0.5:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$29.38B

P/E (fwd)

-29.2

52-week range

$19.79–$42.50

Off 52-week high

5.2%

RSI (14)

63

Volume vs avg

0.41×

Score today

4.2/10